AstraZeneca’s Full Takeover of SixPeaks Bio: Strategic Snapshot
Global biopharmaceutical company AstraZeneca’s option exercise to acquire the remaining equity of Swiss biotechnology startup SixPeaks Bio AG marks a calculated push into the fast-growing obesity and metabolic-health arena. The deal converts AstraZeneca’s 2024 minority stake into full ownership. After a US $15 million seed investment last year, AstraZeneca paid $170 million at closing, will remit $30 million in two years, and…